Immune Thrombocytopenia
An autoimmune disorder characterized by low platelet counts (<100,000/μL) due to immune-mediated platelet destruction and impaired production. Causes increased bleeding risk. Previously called idiopathic thrombocytopenic purpura (ITP).
Quick Answer
What it is
An autoimmune disorder characterized by low platelet counts (<100,000/μL) due to immune-mediated platelet destruction and impaired production. Causes increased bleeding risk.
Key findings
- Grade A: Durable Platelet Response (Romiplostim (Nplate))
- Grade A: Overall Platelet Response (Romiplostim (Nplate))
- Grade A: Long-term Efficacy (Romiplostim (Nplate))
Safety
- Causes increased bleeding risk.
- Safe long-term with no increased thrombosis or malignancy risk.
ℹ️ Quick Facts
Quick Facts: Immune Thrombocytopenia
- Supplements Studied:1
1 supps · 4 outcomes
Detailed Outcomes
A
Durable Platelet Response
Phase 3: 38% durable response (≥50,000/μL for ≥6 of last 8 weeks) in splenectomized vs 0% placebo (P=0.0013). 52% durable response in pediatric patients vs 10% placebo (P=0.002, OR 9.1).
large↑Improves
A
Overall Platelet Response
Phase 3: 88% non-splenectomized and 79% splenectomized achieved platelet response vs 14% and 0% placebo (P<0.0001). Mean 13.8 weeks with platelets ≥50,000/μL vs 0.8 weeks placebo.
large↑Improves
A
Long-term Efficacy
5-year extension: 95% achieved platelet response at least once. Platelet response maintained at median 92% of visits. Stable doses (mean 5-8 μg/kg) with platelets 50-200,000/μL throughout.
large↑Improves
A
Bleeding Reduction
Reduced bleeding events vs placebo. Lower rescue medication use. Decreased need for concurrent ITP therapies. Safe long-term with no increased thrombosis or malignancy risk.
large↓Improves